# Collaborating with Academia

Scott V. Dindot, Ph.D.

Associate Professor | Texas A&M University
Executive Director Molecular Genetics | Ultragenyx Pharmaceutical
May 16, 2024

Ultragenyx Pharmaceutical RARE Entrepreneurship Bootcamp







My opinions are based on my experiences and perspective.

I use a cynical tactic to illustrate the nuances — albeit factual — of collaborating with academic researchers.

Every investigator, department, and institution is different.

# My Background

Tenured Faculty Member, Texas A&M University (2008-present)

Chief Scientific Officer, GeneTx Biotherapeutics (2017-2020)

 Executive Director Molecular Genetics, Ultragenyx Pharmaceutical (2020-present)




# My Background

• Continuous funding from federal agencies, foundations, companies, and licensing agreements.

• 15 years collaborating with rare disease foundations.

Collaborating with Academia






# The GOOD



# The First Molecular Therapy for Angelman Syndrome to Advance into Clinical Development













# the BAD and the UGLY



## Academic Research


The largest flea markets in the world





### Academic Research

### The currency of our trade is measured in grant dollars and publications





Human Molecular Genetics, 2008, Vol. 17, No. 1 111-118 Advance Access published on October 16, 2007

#### The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology

Scott V. Dindot<sup>1</sup>, Barbara A. Antalffy<sup>1,2</sup>, Meenakshi B. Bhattacharjee<sup>2</sup> and Arthur L. Beaudet<sup>1,\*</sup>

<sup>1</sup>Department of Molecular and Human Genetics and <sup>2</sup>Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

Received August 24, 2007; Revised and Accepted September 27, 2007

Loss of function of the maternally inherited allele for the UBE3A ubiquitin ligase gene causes Angelman syndrome (AS), which is characterized by severe neurological impairment and motor dysfunction. In addition, UBE3A lies within chromosome 15q11-q13 region, where maternal, but not paternal, duplications cause autism. The UBE3A gene product, E6-AP, has been shown to function both as an E3 ligase in the ubiquitin proteasome pathway and as a transcriptional coactivator. However, the specific role of E6-AP in the brain, or how loss of function of E6-AP results in AS, is unclear. Herein, we show, using a recombinant transgenic mouse expressing a Ube3a YFP fusion gene, that the maternal Ube3a YFP allele is upregulated and preferentially expressed in neurons, and that the fusion protein, E6-AP:YFP, is enriched in the nucleus and dendrites in vivo. We also show that E6-AP:YFP localizes to the nucleus and to presynaptic and postsynaptic compartments in cultured hippocampal neurons. Furthermore, we show that cerebellar Purkinje cell number and dendritic branching are not affected in Ube3a maternal-deficient mice, but that dendritic spine development, including spine morphology, number and length, is affected on cerebellar Purkinje cells and on pyramidal neurons in the hippocampus and cortex. Collectively, these data suggest that the neurological deficits observed in AS patients and in AS mice may result from specific abnormalities in synaptic development and/ or plasticity.

#### INTRODUCTION

Angelman syndrome (AS) is characterized by severe mental have defects in long-term potentiation (LTP) and manifest retardation, absence of speech, ataxia and a happy disposition motor and behavioral abnormalities that parallel findings in (1,2). The AS gene, UBE3A, encodes the E6-AP ubiquitin AS in spite of normal cellular architecture in the brain (9). ligase and is subject to genomic imprinting, with preferential The neurological deficits in AS mice have been directly maternal-specific expression in brain and, more specifically, in linked to the postsynaptic calcium/calmodulin kinase type neurons but not in glia (3,4). Maternal but not paternal inters- (CaMKII) signaling pathway, as AS mice have increased titial duplications of chromosome 15q11-q13 cause autism inhibitory phosphorylation of αCaMKII in the brain (10) (5). These duplications encompass multiple genes, but Moreover, the learning and behavioral deficits present in AS UBE3A is a strong candidate to contribute to the autism mice can be rescued through a mutation in CaMKII that pre phenotype in 15q11-q13 duplication cases based on its vents its inhibitory phosphorylation (11). Other reports have imprinted status and known causative role in AS (6). Autism linked E6-AP to various neurologically relevant proteins spectrum disorders are seen with Prader-Willi syndrome including epithelial cell-transforming sequence 2 oncogene and AS, the two phenotypes associated with paternal and (Ect2) (12), neuronal protein interacting specifically with maternal deletions of 15q11-q13, respectively (7,8).

Mice with a maternal null mutation in Uhe3a (AS mice) TC10 (nPIST) (13) and myc-binding protein-2 (MYCBP2)




<sup>\*</sup>To whom correspondence should be addressed. Tel: +1 7137984795; Fax: +1 7137987773; Email: abeaudet@bcm.tmc.edu

<sup>©</sup> The Author 2007, Published by Oxford University Press, All rights reserved For Permissions, please email: journals.permissions@oxfordjournals.org

### Scientific Articles

There are too many of them, and most of them are wrong or biased





#### A PROPOSED STRUCTURE FOR THE NUCLEIC ACIDS

#### By Linus Pauling and Robert B. Corey

### GATES AND CRELLIN LABORATORIES OF CHEMISTRY,\* CALIFORNIA INSTITUTE OF TECHNOLOGY

Communicated December 31, 1952




FIGURE 4

Perspective drawing of a portion of the nucleic acid structure, showing the phosphate tetrahedra near the axis of the molecule, the  $\beta$ -D-ribofuranose rings connecting the tetrahedra into chains, and the attached purine and pyrimidine rings (represented as purine rings in this drawing). The molecule is inverted with respect to the coordinates given in table 1.

> Proc Natl Acad Sci U S A. 1953 Feb;39(2):84-97. doi: 10.1073/pnas.39.2.84.

#### A Proposed Structure For The Nucleic Acids


L Pauling 1, R B Corey

Affiliations + expand

PMID: 16578429 PMCID: PMC1063734 DOI: 10.1073/pnas.39.2.84

Free PMC article






**Linus Carl Pauling** 

Nobel Peace Prize 1954 and 1962

# MOLECULAR STRUCTURE OF NUCLEIC ACIDS

### A Structure for Deoxyribose Nucleic Acid



This figure is purely diagrammatic. The two ribbons symbolize the two phosphate—sugar chains, and the horizontal rods the pairs of bases holding the chains together. The vertical line marks the fibre axis


> Nature. 1953 Apr 25;171(4356):737-8. doi: 10.1038/171737a0.

Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid

J D WATSON, F H CRICK

PMID: 13054692 DOI: 10.1038/171737a0






**James Watson and Francis Crick** 

Nobel Peace Prize 1962



## Academic Research

An unusual business model involving the most unusual people





# **Academic Collaborators**


### One collaborator is many partners with different priorities

### **Principal Investigator Priorities**

- Tenure and Promotion
- Solvency
- Trainees

### Other priorities

- Teaching
- Lab/personnel situations
- Risk
- Competition



#### **Institutional Priorities**

- Academic freedom
- Protecting faculty and trainees
- Intellectual property


#### Other priorities

- Business model
- National status
- Politics
- Internal initiatives




# Your Journey with an Academic Collaborator

## Expectation





# Your Journey with an Academic Collaborator *Reality*





### Conclusions

- Academic research is the engine that drives innovation, but it is a unique and often misunderstood ecosystem try to understand it.
- Find a collaborator who understands your objectives and timelines, and try to understand their objectives and timelines every person and situation is different.
- Trust your academic collaborator, but do not make assumptions about their situation, environment, institution, etc. find out as much as you can as early as possible.
- Be dubious about scientific publications, scientific claims, timelines, etc. it is the nature of research to embellish and overpromise.
- Be focused, but expect twists and turns and failures and frustrations they are inevitable.



# Thank you!

sdindot@tamu.edu



